<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03258749</url>
  </required_header>
  <id_info>
    <org_study_id>KY2017-009</org_study_id>
    <nct_id>NCT03258749</nct_id>
  </id_info>
  <brief_title>Efficiency of Twice Daily Formoterol Versus Once Daily Tiotropium in Patients With GOLD A/B COPD</brief_title>
  <acronym>FACT</acronym>
  <official_title>Efficiency of Twice Daily Formoterol Versus Once Daily Tiotropium in Patients With GOLD A/B COPD: a Randomised, Open-label, Multicentre Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Huashan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Huashan Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic obstructive pulmonary disease (COPD) is a disease state characterized by persistent
      airflow limitation and associated with an accelerated decline in lung function, impaired
      quality of life, hospitalization, and increased mortality. As a major public health problem,
      COPD is predicted to rank as the fifth burden of diseases in the world by 2020. Thus,
      prevention of exacerbations is a important goal in the management of COPD. The Global
      Initiative for Chronic Obstructive Lung Disease (GOLD) Scientific Committee launched a joint
      project in 1998. Its goals were to raise awareness of COPD and to improve prevention and
      treatment of COPD patients around the world. In the 2017 GOLD guidelines, inhaled long-acting
      bronchodilators, including inhaled long-acting muscarinic antagonists (LAMAs) and inhaled
      long-acting beta-agonists (LABAs), are recommended for the management of all stable COPD
      patients. However, it is not known whether LABA or LAMA will be more effective for initial
      relief of symptoms in patients with GOLD A/B COPD. In this multicenter, randomized study, the
      investigators evaluate the efficacy of formoterol(LABA) and tiotropium(LAMA) in the treatment
      of patients with GOLD A/B COPD. The primary endpoint is postbronchodilator FEV1, and the
      secondary endpoints include the frequency of COPD exacerbation, other lung function
      parameters, CCQ score and mMRC/CAT score.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2017</start_date>
  <completion_date type="Anticipated">October 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>postbronchodilator FEV1</measure>
    <time_frame>12 months</time_frame>
    <description>a post-bronchodilator forced expiratory volume in one second</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>the frequency of COPD exacerbation</measure>
    <time_frame>12 months</time_frame>
    <description>the frequency of COPD exacerbation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>other lung function parameters</measure>
    <time_frame>12 months</time_frame>
    <description>other lung function parameters(%FEV1, FEV1/FVC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CCQ score</measure>
    <time_frame>12 months</time_frame>
    <description>Clinical COPD Questionnaire score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mMRC score</measure>
    <time_frame>12 months</time_frame>
    <description>modified Medical Research Council score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CAT score</measure>
    <time_frame>12 months</time_frame>
    <description>COPD Assessment Test score</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>Formoterol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>inhaled formoterol(4.5μg, bid)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tiotropium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>inhaled Tiotropium(18μg, qd)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiotropium</intervention_name>
    <description>inhaled Tiotropium(18μg, qd)</description>
    <arm_group_label>Tiotropium</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Formoterol</intervention_name>
    <description>inhaled formoterol(4.5μg, bid)</description>
    <arm_group_label>Formoterol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Clinical diagnosis of group A or group B stable COPD. Must be able to inhale Formoterol or
        Tiotropium.

        Exclusion Criteria:

        Asthma. Cystic fibrosis. Bronchiectasis. Lung cancer. Glaucoma. Tachyarrhythmia or other
        serious heart diseases. Prostatic hyperplasia.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shengqing Li, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Huashan Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shengqing Li, PhD</last_name>
    <phone>+8602152887072</phone>
    <email>shengqingli@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Peng Zhang, MD</last_name>
    <phone>+8602152887073</phone>
    <email>chang0311@foxmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Huashan hospital,Fudan university</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200040</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shengqing Li, PhD</last_name>
      <phone>+8602152887072</phone>
      <email>shengqingli@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Peng Zhang, MD</last_name>
      <phone>+8602152887073</phone>
      <email>chang0311@foxmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 13, 2017</study_first_submitted>
  <study_first_submitted_qc>August 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 23, 2017</study_first_posted>
  <last_update_submitted>October 18, 2017</last_update_submitted>
  <last_update_submitted_qc>October 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Huashan Hospital</investigator_affiliation>
    <investigator_full_name>Shengqing Li</investigator_full_name>
    <investigator_title>Chief Physician,Professor</investigator_title>
  </responsible_party>
  <keyword>COPD</keyword>
  <keyword>GOLD</keyword>
  <keyword>formoterol</keyword>
  <keyword>tiotropium</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Formoterol Fumarate</mesh_term>
    <mesh_term>Tiotropium Bromide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

